Login to Your Account

Baxter Chooses Halozyme Again; Firms Collaborate On SC IVIG

By Jennifer Boggs

Tuesday, September 11, 2007
Halozyme Therapeutics Inc. could earn up to $47 million in its latest deal with Baxter International Inc., which aims to develop a subcutaneous version of Gammagard, Baxter's intravenous immune globulin (IVIG) product approved for primary immunodeficiency disorders. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription